Since KCTD10 downregulates β-catenin and PD-L1, and PD-L1 expression is known to promote tumor immune evasion in lung cancer (52), we investigated the impact of KCTD10 on lung cancer immunotherapy. Here, KCTD10 is linked to lung carcinoma.